BOARD CHANGE

RNS Number : 2491D

ConvaTec Group PLC

25 June 2019

 

BOARD CHANGE

Reading, United Kingdom (25 June 2019) - Jesper Ovesen has advised the Board of ConvaTec Group Plc ("ConvaTec" or "the Company") that he wishes to retire as a Non-Executive Director of the Company on 28^th June 2019.

Margaret Ewing, Senior Independent Director, will succeed Jesper as Chair of the Audit and Risk Committee and Regina Benjamin will also become a member of the Committee. Regina will also be appointed as a member of the Remuneration Committee. These appointments will take effect from 28^th June.

Margaret joined the Board of ConvaTec in August 2017. She has strong executive and non-executive experience with large listed businesses and is currently a Non-Executive Director and Chair of the Audit and Risk Committee of ITV plc and a Non-Executive Director and member of the Audit and Compliance Committee of International Airlines Group plc. She was previously CFO of BAA plc and Trinity Mirror plc and Executive Board member of Deloitte LLP.

Rick Anderson, Executive Chairman, commented "On behalf of the Board I would like to thank Jesper for his valuable contribution to ConvaTec since he became a Director in 2016.

We are very pleased that Margaret has agreed to become the Chair of the Audit and Risk Committee, where her knowledge and experience will be most valuable to ConvaTec."

This announcement is made in accordance with Listing Rule 9.6.11R(1).

Enquiries:

Analysts and Investors
John Crosse, VP Investor Relations	[phone]
Mark Reynolds, Director Investor Relations [e-mail]	[phone]
Media
Bobby Leach, VP Group Corporate Affairs	[phone]
Finsbury	[phone]

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

 

END

 

 

BOAFIMATMBATBML